scholarly journals Recent trends in incidence and mortality rates for leukemias, and in survival rates for childhood acute lymphocytic leukemia, in upstate New York

Cancer ◽  
1986 ◽  
Vol 57 (9) ◽  
pp. 1850-1858 ◽  
Author(s):  
Anthony P. Polednak
Keyword(s):  
New York ◽  
Acute Lymphocytic Leukemia ◽  
Survival Rates ◽  
Mortality Rates ◽  
Lymphocytic Leukemia ◽  
Upstate New York ◽  
Incidence And Mortality ◽  
Recent Trends

scholarly journals Cancer in Africa: Is It a Genetic or Environmental Health Problem?

2020 ◽  
Vol 10 ◽  
Author(s):  
Abeer A. Bahnassy ◽  
Mona S. Abdellateif ◽  
Abdel-Rahman N. Zekri
Keyword(s):  
Health Problem ◽  
African Ancestry ◽  
Survival Rates ◽  
Mortality Rates ◽  
Sociocultural Factors ◽  
Major Health Problem ◽  
Major Health ◽  
Incidence And Mortality ◽  
Environmental Health Problem ◽  
African Patients

Patients of African ancestry have the poorest outcome and the shortest survival rates from cancer globally. This could be attributed to many variables including racial, biological, socioeconomic and sociocultural factors (either single, multiple or combined), which may be responsible for this major health problem. We sought to assess the most common types of cancer that endanger the health of the African people, and tried to investigate the real differences between African and other Non-African patients regarding incidence, prevalence and mortality rates of different cancers. Therefore, identifying the underlying aetiological causes responsible for the increased incidence and mortality rates of African patients will allow for changing the current plans, to make optimized modalities for proper screening, diagnosis and treatment for those African patients, in order to improve their survival and outcomes.

scholarly journals Colorectal Cancer Incidence and Mortality Rates Among New York City Adults Ages 20–54 years during 1976–2015

2018 ◽  
Vol 2 (4) ◽  
Author(s):  
Kellie C Van Beck ◽  
John Jasek ◽  
Kristi Roods ◽  
Jennifer J Brown ◽  
Shannon M Farley ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
New York ◽  
New York City ◽  
York City ◽  
New York State ◽  
Mortality Rates ◽  
Registry Data ◽  
Mortality Trends ◽  
Annual Percent Change ◽  
Incidence And Mortality

Abstract Colorectal cancer (CRC) incidence rates are rising in younger Americans and mortality rates are increasing among younger white Americans. We used New York State Cancer Registry data to examine New York City CRC incidence and mortality trends among adults ages 20–54 years by race from 1976 to 2015. Annual percent change (APC) was considered statistically significant at P less than .05 using a two-sided test. CRC incidence increased among those ages 20–49 years, yet blacks had the largest APC of 2.2% (1993–2015; 95% confidence interval [CI] = 1.4% to 3.1%) compared with 0.5% in whites (1976–2015; 95% CI = 0.2% to 0.7%). Among those aged 50–54 years, incidence increased among blacks by 0.8% annually (1976–2015; 95% CI = 0.4% to 1.1%), but not among whites. CRC mortality decreased among both age and race groups. These findings emphasize the value of local registry data to understand trends locally, the importance of timely screening, and the need for clinicians to consider CRC among all patients with compatible signs and symptoms.

Solitary Plasmacytoma Incidence, Mortality, and Survival Trends in the United States

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5629-5629
Author(s):  
Anirudh Bikmal ◽  
Lakshmi Radhakrishnan ◽  
Ajay K. Nooka
Keyword(s):  
Regression Analysis ◽  
Black Males ◽  
Survival Rates ◽  
The United States ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Study Cohort ◽  
Solitary Plasmacytoma ◽  
Incidence And Mortality ◽  
Adjusted Incidence

Abstract Background: The trends of incidence of solitary bone plasmacytoma (SBP) varied over time due to the changing definitions and the absence of clarity of the criteria. Prior studies have attempted to identify factors such as older age, gender, race as prognostic factors that influence survival of patients with SBP, but with changing paradigm of myeloma treatments, there is limited literature regarding the incidence, mortality and survival trends of SBP. Methods: We used the SEER registry from 1973-2009 to evaluate the incidence, mortality and survival trends in patients with SBP. The results were reported as crude incidence, mortality and survival rates. Two-sample t-tests, ANOVA as well regression analysis were used to examine correlation. Statistics were computed using the National Cancer Institute SEER*Stat software, version 8.2.0. and SAS software, version 9.4 (SAS Institute Inc, Cary, NC). Using the ICD-O-3 and morphologic codes of 9731/3 to identify cases, the final study cohort consisted of 2,734 cases. Trends were evaluated by the eras of diagnosis: 1973-1980, 1981-1985, 1986-1990, 1991-1995, 1996-2000, 2001-2005, and 2006-2009. Age-adjusted incidence rates (IR), standard mortality rates (SMR), survival rate (SR) were expressed as new cases per 100,000 person-years, and age-adjusted to the 2000 US standard population. Results: The median age of diagnosis of SBP among blacks is 61 years (range, 21-91) compared to others: 60 years (range, 28-88) and whites: 66 years (20-97). The age adjusted incidence rates for black males is: 0.3 (95%CI 0.2, 0.3) followed by black females 0.2 (95%CI 0.1, 0.2) white males 0.2 (95%CI 0.2, 0.2) white females 0.1 (95%CI 0.1, 0.1). The trends in incidence and mortality rates are illustrated in table 1 with highest IR noted for black males during the era 2006-2009. The 5-year survival rates for both males (figure 1) and females (figure 2) seem to be trending down over the eras examined. Regression analysis suggests males and other race have increased odds of survival (HR = 0.829, p=0.0078; HR = 0.54 and p=0.0038, respectively). Conclusions: Similar to myeloma, black patients tend to be diagnosed with SBP younger and have increased incidence. The incidence rates seem to be increasing, highest among blacks males, more likely from increased awareness and diagnosis. The mortality and survival patterns are comparable to whites. Interestingly, while the 5-year survival for myeloma among all racial groups is improving this analysis shows a decreasing trend for SBP. This observation is more likely from including myeloma patients under the diagnosis of SBP over the period of study. Recently, the International Myeloma Working Group (IMWG) clarified the definition of SBP which will help in accurate diagnosis and ultimately can help in accurate representation of the survival trends. Table 1. Incidence and Mortality Rates across Study Eras (SEER-9), 1973-2009 Years White (IR) White (MR) Black (IR) Black (MR) Other (IR) Other (MR) Male 1973-1980 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.1) 1981-1985 0 0 0 (0, 0.2) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.1) 1986-1990 0.1 (0.1, 0.2) 0.1 (0, 0.1) 0.1 (0, 0.3) 0.1 (0, 0.2) 0.3 (0.1, 0.5) 0 (0, 0.2) 1991-1995 0.2 (0.1, 0.2) 0.1 (0.1, 0.2) 0.2 (0.1, 0.4) 0 (0, 0.1) 0.1 (0, 0.3) 0.1 (0, 0.2) 1996-2000 0.2 (0.2, 0.3) 0.1 (0.1, 0.1) 0.3 (0.1, 0.5) 0.2 (0.1, 0.4) 0.2 (0.1, 0.4) 0.2 (0, 0.4) 2001-2005 0.4 (0.4, 0.5) 0.2 (0.2, 0.3) 0.5 (0.3, 0.7) 0.3 (0.1, 0.6) 0.2 (0, 0.2) 0 (0, 0.2) 2006-2009 0.4 (0.4, 0.5) 0.2 (0.2, 0.3) 0.7 (0.4, 1) 0.3 (0.1, 0.5) 0.1 (0, 0.2) 0.1 (0, 0.2) Female 1973-1980 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 1981-1985 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 1986-1990 0.1 (0, 0.1) 0 (0, 0.1) 0.1 (0, 0.2) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.2) 1991-1995 0.1 (0.1, 0.1) 0 (0, 0.1) 0.2 (0.1, 0.3) 0.1 (0, 0.2) 0 (0, 0.1) 0 (0, 0.1) 1996-2000 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0, 0.2) 0.1 (0, 0.2) 0.1 (0.2) 0 (0, 0.1) 2001-2005 0.2 (0.2, 0.2) 0.1 (0.1, 0.2) 0.3 (0.2, 0.4) 0.1 (0, 0.2) 0.1 (0, 0.2) 0 (0, 0.1) 2006-2009 0.2 (0.2, 0.3) 0.1 (0.1, 0.2) 0.3 (0.2, 0.5) 0.2 (0.1, 0.3) 0.1 (0, 0.2) 0 (0, 0.1) Figure 1. 5-year Survival Rates in males (SEER-9), 1973-2012 Figure 1. 5-year Survival Rates in males (SEER-9), 1973-2012 Figure 2. 5-year Survival Rates in females (SEER-9), 1973-2012 Figure 2. 5-year Survival Rates in females (SEER-9), 1973-2012 Disclosures Nooka: Spectrum Pharmaceuticals: Consultancy; Onyx Pharmaceuticals: Consultancy.

Ten Years of Experience with Invasive Aspergillosis: Has Anything Changed?.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3687-3687
Author(s):  
Gloria Mattiuzzi ◽  
Jorge Cortes ◽  
Jennifer Ho ◽  
Hagop M. Kantarjian
Keyword(s):  
Mortality Rate ◽  
Invasive Aspergillosis ◽  
Hematologic Malignancies ◽  
Mortality Rates ◽  
Antifungal Drugs ◽  
Lymphocytic Leukemia ◽  
Myelogenous Leukemia ◽  
Myelocytic Leukemia ◽  
Incidence And Mortality ◽  
The Moment

Abstract Abstract 3687 Poster Board III-623 Invasive Aspergillosis (IA) has represented a threat for patients and physicians for many years. This is especially true for patients with hematologic malignancies. Several new antifungal agents with broad antifungal activity became available in 2000 ushering in a new millennium with hopes that with this new armamentarium of antifungal drugs will decrease mortality due to IA and perhaps even prevent them better. Mortality rates due to IA have been described in recent reports as acceptable and even in some cancer centers significantly lower than before. The objective of the present study was to evaluate IA in patients with hematologic malignancies in the leukemia department at MDACC during the past 10 years (1998 to 2007) and compare the incidence and mortality rates between these two times periods. Methods retrospective review of all patients that presented at the leukemia department at MDACC from January 1998 to December 2007. Proven or probable IA was defined as per EORTC criteria. Results From 1998 to 2007, 12,845 patients were presented to our department, including 4,243 pts with acute myelogenous leukemia (AML); 940 with acute lymphocytic leukemia (ALL); 3,642 with chronic lymphocytic leukemia (CLL); and 4,276 with other type of leukemia (chronic myelocytic leukemia, low risk-myelodysplastic syndrome and miscellaneous). Overall median age was 58 (range 17-83); 60% were male, 83% did not have history of diabetes mellitus; 71% were neutropenic (ANC < 500) at the moment of the infection; and 11% had a previous bone marrow transplantation. The overall incidence of IA has significantly decreased from 4 % to 2% over the 10 study years (p= 0.005, IRR=0.45), however, the overall mortality rate (60%) has not decreased significantly. Comparison between the incidence of IA and mortality in the different subsets of patients between 1998-1999 and 2000-2007 is shown in Table 1 The incidence of IA decreased significantly between the two time periods only in patients with AML and in patients with ALL (p<0.001 and 0.004, respectively). However, although there has been a reduction in the mortality rate in all the subsets of patients in the two periods, this difference is not significant. Overall, A. fumigatus was the pathogen more frequently isolated (30%), followed by A. flavus (21%), A. terreus (18%) and A. niger (11%). In 10% of the episodes more than one Aspergillus species was isolated. In conclusion, our data suggests that the incidence of IA in patients with leukemia traditionally at high risk for IA has significantly decreased since 2000. Despite the availability of new antifungal drugs for the treatment of IA, the mortality rate in patients with hematological malignancies has not significantly decreased. Disclosures: Mattiuzzi: Merck: Research Funding.

scholarly journals Survival rate of cervical cancer from a study conducted in India

2020 ◽  
Vol 0 ◽  
pp. 1-10
Author(s):  
Ganesh Balasubramaniam ◽  
Rajshree H. Gaidhani ◽  
Arshi Khan ◽  
Sushama Saoba ◽  
Umesh Mahantshetty ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Survival Rate ◽  
Early Stage ◽  
Survival Rates ◽  
Care Facility ◽  
Mortality Rates ◽  
Survival Outcomes ◽  
Stage Of Disease ◽  
Treatment Type ◽  
Incidence And Mortality

Objectives: The incidence and mortality rates of cervical cancer in the world are 13.1/105 and 6.9/105, respectively. In India, it is estimated that there are 96,922 new cervical cancer cases and 60,078 deaths and ranked second among women cancers. The incidence and mortality rates are 14.7/105 and 9.2/105, respectively, although the incidence varies within Indian population. The majority of these cervical patients report at a late-stage of disease in health-care facility due to lack of awareness. A premier tertiary cancer hospital in Mumbai conducted the present survival-study. The aim of the study was to assess the various factors that determine the survival outcomes by age at diagnosis, role of comorbidities, stage of disease, and treatment. Material and Methods: The main source of information was patients’ medical records from which the data were abstracted, and active follow-up was undertaken. 1678 cases diagnosed between the years 2006 and 2008 at Tata Memorial Hospital are analyzed using actuarial method for obtaining survival rates and log-rank tests for comparison of survival groups. Results: The 5-year survival rate was 76.0% for those aged ≤50 years, 73.3% for non-residents, 74.4% for literates, and 81.8% for Christians and 72.5% for those with squamous cell carcinoma histology; those with no comorbidities had marginally better survival than their counter-parts. The survival rates were 83.5%, 80.6%, 66.0%, and 37.1% for Stage I, Stage II, Stage III, and Stage IV, respectively. The best survival outcomes were for those treated with only surgery (95.6%), or in combination with either radiotherapy (90.6%) or with radiotherapy and chemotherapy (85.5%). Involvement of either nodes/sites had poorer survival than those with no-involvement. In the multivariate analysis, only stage of the disease emerged as a significant prognosis factor. Conclusion: The study concluded that younger patients, early stage of disease, non-involvement of any sites/ nodes, and radiotherapy either alone or in combination with other treatment type provided better outcomes. Early detection and prevention strategies are keys to obtain better outcomes.

scholarly journals Survival, Growth and Establishment of Grafted Pawpaws in Upstate New York

2003 ◽  
Vol 13 (3) ◽  
pp. 421-422 ◽  
Author(s):  
Ian A. Merwin ◽  
Rachel Byard ◽  
Kirk W. Pomper
Keyword(s):  
New York ◽  
Block Design ◽  
Survival Rates ◽  
Winter Mortality ◽  
Cornell University ◽  
Upstate New York ◽  
Asimina Triloba ◽  
Randomized Block Design ◽  
Black Plastic ◽  
Open Mesh

A pawpaw regional variety trial (PRVT) was established at Cornell University, Ithaca, N.Y. in Apr. 1999 consisting of 28 commercially available pawpaw (Asimina triloba) varieties or advanced selections from the PawPaw Foundation (PPF; Frankfort, Ky.). Eight replicate trees of each selection, grafted onto seedling rootstocks, were planted in a randomized block design. The first two winters at the test planting site were unusually mild for the Finger Lakes region, with the lowest recorded temperatures above -16 °C (3.2 °F). Despite these mild winters, there was extensive winter mortality of some pawpaw varieties. Survival rates were >75% for 11 varieties, and were <40% for five other varieties. Poor establishment of grafted clonal pawpaws and insufficient pollination or fertilization of established pawpaws were important limitations of successful commercialization of this new fruit crop under conditions typical of upstate New York. Open mesh black plastic trunk guards provided adequate shade and protection for newly planted pawpaws, whereas translucent plastic tree-tubes caused heat stress and scorching of the young trees.

Time Trends in Survival of Children with Acute Lymphocytic Leukemia in Piedmont, Italy: A Report from the Population-Based Cancer Registry

1995 ◽  
Vol 81 (3) ◽  
pp. 164-168 ◽  
Author(s):  
Corrado Magnani ◽  
Enrica Pazè ◽  
Benedetto Terracini ◽  
Guido Pastore ◽  
Maria Luisa Mosso
Keyword(s):  
Cancer Registry ◽  
Time Trends ◽  
Acute Lymphocytic Leukemia ◽  
Present Report ◽  
Survival Rates ◽  
Population Based ◽  
Lymphocytic Leukemia ◽  
Probability Of Survival ◽  
Wbc Count ◽  
Improvement In Survival

Aims and Background The Childhood Cancer Registry of Piedmont (RTI) periodically updates the life status of each registered child. Given its size, the RTI is the major (albeit geographically limited) Italian source of population-based survival rates of cancer in children. The present report describes time trends in survival of children with acute lymphocytic leukemia (ALL). Methods During 1970-87, 429 residents in Piedmont aged 0-14 were diagnosed as having ALL: they have been followed up until 1991. Results Five-year survival rates increased from 21% to 72% for children diagnosed ALL respectively in 1970-72 and 1985-87. Major improvements occurred up to the mid-seventies and again between cases diagnosed in the early and late eighties. Improvement in survival was statistically significant for children belonging to classes comprised between 2 and 10 years of age at diagnosis. Period of diagnosis was unrelated to probability of survival among the 13 cases diagnosed ALL at age 0. Survival was unrelated to sex, even in the early seventies and even after consideration of children dying more than 5 years after diagnosis. Between 1976-81 and 1982-87, an improvement in survival was found in all categories of WBC count at diagnosis: the ratio between the two estimates was somewhat higher for children with more than 50,000 WBC/mm3 at diagnosis than for other children. Conclusions Present data are compared with those resulting from other population-based series: this exercise can be useful for an overall evaluation of delivery of cancer therapy at the population basis.

scholarly journals Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005

2009 ◽  
Vol 27 (9) ◽  
pp. 1485-1491 ◽  
Author(s):  
Sean F. Altekruse ◽  
Katherine A. McGlynn ◽  
Marsha E. Reichman
Keyword(s):  
United States ◽  
Hepatocellular Carcinoma ◽  
At Risk ◽  
Cancer Mortality ◽  
Survival Rates ◽  
The United States ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Incidence And Mortality ◽  
Adjusted Incidence

Purpose Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. Incidence rates are increasing in the United States. Monitoring incidence, survival, and mortality rates within at-risk populations can facilitate control efforts. Methods Age-adjusted incidence trends for HCC were examined in the Surveillance, Epidemiology, and End Results (SEER) registries from 1975 to 2005. Age-specific rates were examined for birth cohorts born between 1900 and 1959. Age-adjusted incidence and cause-specific survival rates from 1992 to 2005 were examined in the SEER 13 registries by race/ethnicity, stage, and treatment. United States liver cancer mortality rates were also examined. Results Age-adjusted HCC incidence rates tripled between 1975 and 2005. Incidence rates increased in each 10-year birth cohort from 1900 through the 1950s. Asians/Pacific Islanders had higher incidence and mortality rates than other racial/ethnic groups, but experienced a significant decrease in mortality rates over time. From 2000 to 2005, marked increases in incidence rates occurred among Hispanic, black, and white middle-aged men. Between 1992 and 2004, 2- to 4-year HCC survival rates doubled, as more patients were diagnosed with localized and regional HCC and prognosis improved, particularly for patients with reported treatment. Recent 1-year survival rates remained, however, less than 50%. Conclusion HCC incidence and mortality rates continue to increase, particularly among middle-aged black, Hispanic, and white men. Screening of at-risk groups and treatment of localized-stage tumors may contribute to increasing HCC survival rates in the United States. More progress is needed.

Sign in / Sign up

Export Citation Format

Share Document